| The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology EJ Gardner, VK Lam, DN Harris, NT Chuang, EC Scott, WS Pittard, ... Genome research 27 (11), 1916-1929, 2017 | 327 | 2017 |
| A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer EC Scott, EJ Gardner, A Masood, NT Chuang, PM Vertino, SE Devine Genome research 26 (6), 745-755, 2016 | 286 | 2016 |
| The Role of Somatic L1 Retrotransposition in Human Cancers EC Scott, SE Devine Viruses 9 (6), 131, 2017 | 96 | 2017 |
| Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a US Food and Drug Administration systematic analysis KJ Norsworthy, F Mulkey, EC Scott, AF Ward, D Przepiorka, R Charlab, ... Clinical Cancer Research 26 (16), 4280-4288, 2020 | 74 | 2020 |
| Trends in the approval of cancer therapies by the FDA in the twenty-first century EC Scott, AC Baines, Y Gong, R Moore Jr, GE Pamuk, H Saber, ... Nature Reviews Drug Discovery, 1-16, 2023 | 47 | 2023 |
| Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus … D Sondhi, EC Scott, A Chen, NR Hackett, AMS Wong, A Kubiak, ... Human gene therapy 25 (3), 223-239, 2014 | 44 | 2014 |
| Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021 S Agrawal, S Arora, L Amiri-Kordestani, RA de Claro, L Fashoyin-Aje, ... JAMA oncology, 2022 | 23 | 2022 |
| Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1-or IDH2-Mutated Acute Myeloid Leukemia T Ghazanchyan, D Kazandjian, D Przepiorka, KJ Norsworthy, E Scott, ... Blood 132 (Supplement 1), 2815-2815, 2018 | 10 | 2018 |
| Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1-or IDH2-Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data EC Scott, K Kural, S Smith, M Colgan, AJ Ambinder, G Ghiaur, N Holmes, ... Blood 138, 1285, 2021 | 1 | 2021 |
| Emerging oncology drug targets in the 21st century: An FDA analysis. EC Scott, Y Gong, A Subedee, D Kazandjian, R Pazdur, VA Rao, ... Journal of Clinical Oncology 38 (15_suppl), e14067-e14067, 2020 | 1 | 2020 |
| T-cell receptor repertoire analysis by next-generation sequencing peripheral blood mononuclear cells from multiple myeloma or smoldering multiple myeloma patients Y Zhang, S Petrovskaya, EC Scott, L Santana-Quintero, T Ghazanchyan, ... Cancer Research 79 (13 Supplement), 5141-5141, 2019 | | 2019 |
| A genomics model to predict immune-related adverse events in cancer patients treated with checkpoint inhibitors EC Scott, D Kazandjian, L Santana-Quintero, T Ghazanchyan, ... Cancer Research 79 (13 Supplement), 3516-3516, 2019 | | 2019 |
| Activity and Regulation of L1 Retrotransposons in Human Genomes EC Scott | | 2017 |
